Latest Hotspot

Phase III EMERALD-1 trial shows Imfinzi plus bevacizumab improves progression-free survival in embolisation-eligible advanced liver cancer

17 November 2023
3 min read

Encouraging top-tier findings from the Phase III EMERALD-1 trial revealed that the combo of AstraZeneca’s Imfinzi (durvalumab) with transarterial chemoembolization and bevacizumab manifested a statistically pertinent and medically significant enhancement in PFS as the prime objective versus TACE alone in patients with hepatocellular carcinoma qualified for embolization. The trial still monitors the secondary endpoint of general survival.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer and ranks third in cancer fatalities, with roughly 900,000 diagnoses globally each year. A technique called embolisation, which obstructs the tumour's blood flow and can directly administer chemotherapy or radiation therapy to the liver, is suitable for approximately 20-30% of patients. 

Despite it being considered the standard treatment in such scenarios, rapid disease escalation or relapse is often experienced by the majority of embolisation recipients. Dr. Riccardo Lencioni, the Director of the Cancer Imaging Program in the Department of Diagnostic and Interventional Radiology at Pisa University Hospital in Pisa, Italy, commented: "The outcomes in utilising durvalumab plus bevacizumab could revolutionize the approach towards treating this challenging disease with a grim prognosis by demonstrating for the first time that incorporating an immunotherapy cocktail to TACE significantly extends progression-free survival." 

AstraZeneca's Executive Vice President of Oncology R&D, Susan Galbraith, said: “These encouraging findings for Imfinzi-based therapy in EMERALD-1 could potentially extend the benefits of immunotherapy to patients in earlier stages of liver cancer. We aim to bring this innovative treatment to patients and are eager to engage in talks with regulatory bodies about these data and observe the maturation of survival data over time."

AstraZeneca is conducting an expansive clinical research program to further investigate Imfinzi in various gastrointestinal cancer scenarios, which includes an adjuvant HCC trial combining Imfinzi with bevacizumab (EMERALD-2), and a study involving tremelimumab, lenvatinib, and TACE for embolisation-eligible HCC (EMERALD-3).

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of November 16, 2023, there are 442 investigational drugs for the PDL1 and integrin target, including 218 indications, 393 R&D institutions involved, with related clinical trials reaching 3020, and as many as 37141 patents.

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. Imfinzi is approved in combination with chemotherapy in locally advanced or metastatic biliary tract cancer and in combination with Imjudo (tremelimumab) in unresectable HCC in the US, EU, Japan and many other countries based on the TOPAZ-1 and HIMALAYA Phase III trials, respectively.

图形用户界面, 文本, 应用程序

描述已自动生成

Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases
Latest Hotspot
3 min read
Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases
17 November 2023
Eccogene acquires unique licensing rights from AstraZeneca to advance and market ECC5004, a small molecule GLP-1 receptor agonist, for cardiovascular metabolic conditions.
Read →
Atezolizumab: brief review of its R&D progress and the clinical result in 2023 ESMO
ESMO 2023
4 min read
Atezolizumab: brief review of its R&D progress and the clinical result in 2023 ESMO
17 November 2023
Atezolizumab plus bevacizumab (AB) is a frequent first-line treatment for advanced hepatocellular carcinoma (HCC), shown superior to sorafenib in the IMbrave150 trial. On October 20, 2023, an Atezolizumab trial was presented at the ESMO Congress.
Read →
Allgenesis announces positive early results for its AG-73305 phase 2a Diabetic Macular Edema study at the American Academy of Ophthalmology
Latest Hotspot
3 min read
Allgenesis announces positive early results for its AG-73305 phase 2a Diabetic Macular Edema study at the American Academy of Ophthalmology
17 November 2023
Allgenesis reports promising initial safety and effectiveness results for AG-73305 phase 2a trial tackling Diabetic Macular Edema, presented at the American Academy of Ophthalmology.
Read →
Takeda Gets Green Light from U.S. FDA to Market FRUZAQLA™ (fruquintinib) for a Pre-treated Type of Advanced Colon Cancer
Latest Hotspot
3 min read
Takeda Gets Green Light from U.S. FDA to Market FRUZAQLA™ (fruquintinib) for a Pre-treated Type of Advanced Colon Cancer
17 November 2023
Takeda has announced FDA approval for its oral drug, FRUZAQLA™ (fruquintinib), designed to treat adults with metastatic colorectal cancer who have previously received chemotherapy, anti-VEGF, and applicable anti-EGFR therapies.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.